close and back to page

Latest News

Latest News

Abbott: Green Efforts Also Good For Business

Abbott's 2020 Environmental Goals are ambitious – and they're helping the planet while reducing costs around the globe.

Sustainability at Abbott (No. 10 on the DiversityInc Top 50 Companies list) isn't a destination, but an ongoing journey. By focusing on the areas where business opportunities intersect with positive social impact, it's also an important way we strengthen the company.

Our ambitious 2020 Environmental Goals drive our efforts around the globe. These goals – highlighted in the newly released 2016 Global Sustainability Report – help us protect the planet while boosting efficiency and reducing costs.

We've identified three environmental priorities – and for each, have set goals for reducing our impact by 2020 (all compared to 2010 levels and adjusted for sales):

  • Reducing Carbon Emissions: A 40 percent decrease in carbon dioxide equivalent (CO2e) emissions associated with our business operations. Through 2016, we've reduced greenhouse gas emissions by 28 percent.
  • Conserving Water: A 30 percent reduction in total water intake. We've reduced our water use by 18 percent through 2016.
  • Reducing Waste: A 50 percent reduction in total waste. By the end of 2016, we reduced waste by 39 percent by reducing it at the source and identifying more opportunities for reuse.

Taken together, in 2016 we launched more than 130 environmental projects around the world to improve waste, water and energy efficiencies. These efforts also are delivering financial benefits to the business, with anticipated 2017 savings of more than 12 percent compared to the company's 2016 environmental expenses.

Thinking Globally, Acting Locally

Michael Kearney is manufacturing shift lead at Abbott's diabetes care facility in Donegal, Ireland. He grew up on the Inishowen Peninsula, a picturesque part of Donegal located at the most northerly point of Ireland. Donegal's natural beauty, pictured above, has inspired National Geographic Traveller magazine to name it the No. 1 location to visit in 2017.

As an 11-year-old student, Kearney developed a love for the environment when he learned about recycling from a schoolteacher. On his family's farm, he encouraged neighbors, friends and family to begin sorting waste and to compost. He's carried this mindset with him to his work at Abbott.

"While it is not part of my core job description, everyone here knows they have a part to play in protecting the environment," he said. "I try to lead by example."

Thanks to Kearney's and his fellow employees' initiative, the Donegal facility received Abbott's "High Performance Award," which recognizes efforts that reduce materials used in production, deliver cost savings and reduce waste. In 2016, the facility team identified opportunities that reduced overall waste generated by 7 percent, and will increase the facility's waste recycling rate to 86 percent in 2017. A further reduction in waste volume also is anticipated in 2017.

"Reducing waste actually makes our day-to-day jobs easier," says Kearney, "and has benefits beyond work to our homes and community. Reducing waste saved our facility alone nearly US$11 million over five years. The small changes we're making add up to a big impact for Abbott and our environment."

Kearney also shares the Donegal facility's environmental best practices outside Abbott's walls. Drawing on his personal experience, he led a waste management awareness program to engage local elementary school students through fun and games. Students took a quiz to test their knowledge about disposing of common household waste through recycling and composting. Through this outreach program, students learned how to better manage waste – and protect their local environment.

Driving Results Across the Business

The work in Donegal is just one example of Abbott's broader approach to protecting the environment. The 2016 Global Sustainability Report shares the broader story and many additional examples, including:

  • Zero Waste Facilities

    Materials sent for reuse now exceed the total waste the company generates globally. As a result, 29 Abbott sites now send zero waste to landfills.

  • Utility Cost Reduction

    We slashed utility costs at our global nutrition business in half, which also reduced energy demand and carbon emissions – achieving our four-year goal ahead of time.

  • LEED Certification

    LEED (Leadership in Energy and Environmental Design) is one of the most respected global benchmarks for environmental efficiency. Taken together, space at Abbott's 14 LEED-certified locations equals nearly 3 million square feet – which is slightly bigger than the landmark Empire State Building in New York City.

In recognition of this work and the company's broader efforts to advance sustainability, Abbott was named the leading company in the Health Care Equipment & Services industry group by the Dow Jones Sustainability Index (DJSI) for the fourth consecutive year in 2016. This marks the 12th consecutive year DJSI recognized Abbott for sustainability leadership, with inclusion on both the Dow Jones Sustainability World Index and North America Index. Abbott also achieved an A- on its CDP (formerly the Carbon Disclosure Project) Climate Change score, placing the company in the "Leadership" Category.

Abbott is all about helping people live their best lives, with good health as the foundation. Helping to protect a healthy environment is an integral part of achieving this mission, while we strengthen our business, every day around the world. To learn more about Abbott's sustainability initiatives, visit

Abbott: Top Internship for Healthcare and Tech

Interns have spoken: Abbott is the top college internship program for healthcare and tech & engineering.

Originally Published by Abbott.

Abbott recognizes the need to develop its future leaders early, and has been named the top healthcare and tech & engineering internship program by Vault.

Read More Show Less

New Study Shows Abbott's Novel Diagnostic Test Could Help Rule Out Heart Attacks Earlier

Preliminary research indicates that a diagnostic test currently in development, that is done at the patient's side in minutes, has similar accuracy to a high-sensitive troponin test for early rule out of a heart attack .

Originally Published by Abbott.

For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether someone is having a heart attack. New data, published online in JAMA Cardiology, found a new blood test under development that is done right at the patient's side in as little as 15 minutes could identify nearly three-fifths (56.7 percent) of people at low-risk of experiencing a heart attack, similar to the results of a High Sensitive Troponin-I blood test done in the laboratory setting.

Read More Show Less

Abbott: Partnering for a Healthier Future

Abbott supports the First Ladies of Africa in the fight to end AIDS in children and keep mothers healthy.

Originally Published by Abbott.

In countries around the world, Abbott is working across its businesses and in partnerships with others to create healthier futures for families. One example: since 2014, Abbott's diagnostics business has supported the work of the Organization of African First Ladies Against HIV/AIDS (OAFLA – pictured above) to fight the AIDS epidemic in Africa, particularly among pregnant women and children – who are among the most vulnerable populations impacted by the disease.

At an OAFLA meeting on the sidelines of the UN General Assembly in New York City, Abbott and several other organizations are being recognized by OAFLA for longstanding partnership and support, including public-private partnerships that bring together technical, financial and other resources to focus on a global health challenge such as HIV/AIDS.

Read More Show Less

Abbott: DRG Stimulator, A Life Changing Technology for Chronic Pain.

The new technological DRG therapy may be the key to easing daily tasks for those with chronic pain.

Originally Published by Abbott.

Living with chronic pain affects not just your body but also your mind. It can make getting around and getting along equally difficult.

But with innovation in health technology comes hope. Abbott has developed a new device found to be more effective than traditional therapy at relieving chronic pain.

Read More Show Less

Abbott: Expediting Blood Testing With i-Stat

The portable, handheld i-STAT Alinity delivers quick blood test results anywhere you are.

Originally Published by Abbott.

Every day, countless blood samples are tested all around the world for one purpose: to help diagnose and treat medical conditions. From the couple eagerly awaiting the results of a pregnancy blood test to a worried cancer patient hoping for more answers, diagnostic blood tests give vital insight into what's happening underneath the skin.

Read More Show Less

Abbott: Freestyle Libre 14 Day, Now FDA Approved

Abbott's flash glucose monitor now FDA-approved for two weeks of use in U.S. between sensor changes.

Originally Published by Abbott.

The U.S. Food and Drug Administration has approved FreeStyle Libre 14 day— Abbott's revolutionary continuous glucose monitoring system. In the U.S., you can wear the sensor up to 14 days with high accuracy.

Read More Show Less

At Abbott, You Look Like An Engineer

Decades before #ILookLikeAnEngineer, Abbott paved the way for a non-profit dedicated to diversity in STEM.

Originally Published by Abbott.


Remember this? A few years ago, a young software engineer was featured in a recruiting advertisement, only to be accused of not being an actual engineer. Frustrated with the assertion, Isis Wenger started a movement to break the stereotype of what an engineer should look like.

Read More Show Less

Abbott Receives FDA Approval for Next-Generation MitraClip Device to Treat People with Leaky Heart Valves

MitraClip is the gold-standard minimally invasive alternative to open-heart surgery for people needing mitral valve repair.

Originally Published by Abbott.

Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for a next-generation version of its leading MitraClip® heart valve repair device used to repair a leaky mitral valve without open-heart surgery. The transcatheter clip-based therapy, now on a third generation of product innovations, has been used to treat more than 65,000 patients worldwide over the last ten years.

Read More Show Less